Tarsus Q2 2026 earnings: XDEMVY sales rise 69% as spending limits loss improvement

Tarsus Pharmaceuticals (NASDAQ: TARS) reported Q2 2026 net product sales and total revenue of $173.9 million, up more than 69% from $102.7 million a year earlier, while basic and diluted net loss per share narrowed to $(0.43) from $(0.48). Higher XDEMVY volume and improved gross-to-net discounts supported growth, but increased commercialization and clinical-development spending limited the improvement in profitability. The company also raised its full-year XDEMVY sales guidance.

Core financial results

XDEMVY accounted for all quarterly revenue, with growth driven by higher sales volume and improved gross-to-net discounts. Gross margin remained high but declined by one percentage point as manufacturing costs, royalties and milestone-payment amortization increased with product sales.

Dollar amounts are in U.S. dollars. No adjusted earnings measures were provided for the quarter.

XDEMVY adoption and pipeline progress

Tarsus reported broader and deeper adoption of XDEMVY. The number of eye care professionals prescribing the treatment at least five times per week doubled year over year. Direct-to-consumer initiatives also contributed to prescription growth and awareness: engagement on XDEMVY.com increased by more than 30% after the new initiatives began, while high-value actions rose 19%.

Unaided awareness of Demodex blepharitis reached approximately 30%, compared with 2% among patients surveyed when the company began its direct-to-consumer campaign. These commercial indicators support management’s view that demand and execution—not only pricing-related factors—contributed to the quarter’s sales growth.

Tarsus also continued expanding beyond XDEMVY through internal development and acquisitions. The following programs contain the company’s principal disclosed clinical milestones:

The iRenix acquisition has been completed, while the Alkeus transaction remained pending at the time of the earnings release. Financial terms for the Alkeus acquisition were not included in the provided materials.

XDEMVY’s gross profit gains were largely absorbed by higher spending

Quarterly gross profit was approximately $161.8 million, up about $65.4 million from the prior-year period. However, combined R&D and SG&A expenses increased by approximately $63.1 million to $181.7 million, leaving only a modest improvement in operating loss despite the substantial increase in product sales.

The higher spending reflected both commercial expansion and pipeline investment. The R&D increase included $8.0 million for the TP-05 Calliope trial, $3.2 million of payroll and personnel costs and $3.1 million of TP-03 program expenses. SG&A growth included $21.2 million of commercial and marketing costs, $19.5 million for patient support, information technology, legal and professional services, and $6.7 million of additional payroll and personnel costs.

This spending pattern shows that Tarsus is using XDEMVY’s growing gross profit to support broader promotion, patient services, staffing and clinical development. The strategy expanded the company’s commercial and development capacity, but it also kept quarterly results in a loss position.

Cash position and balance sheet

Tarsus ended June 2026 with $449.7 million in cash, cash equivalents and marketable securities, consisting of $204.6 million in cash and equivalents and $245.1 million in marketable securities. Long-term debt was $72.8 million.

Current liabilities increased to $175.8 million from $135.7 million at the end of 2025, mainly reflecting higher accounts payable and other accrued liabilities. The company separately announced the pricing of a $125 million private placement on August 6, after the June 30 balance-sheet date; the release described the financing as priced but did not provide closing details in the supplied information.

Full-year guidance

Tarsus raised its full-year 2026 XDEMVY net product sales guidance to $685 million-$705 million. The prior guidance range was not provided, so the size of the increase cannot be quantified from the available information.

For the six months ended June 30, 2026, XDEMVY net product sales totaled $319.3 million. This is a year-to-date figure and is separate from the $173.9 million reported for the second quarter.

Recent insider transactions

The six-month aggregate data showed 229,729 shares purchased across 15 transactions and 154,976 shares sold across 14 transactions, producing net insider purchases of 74,753 shares. The most recent records containing complete sale details involved the CEO, CFO and two directors; these individual transactions should not be interpreted by themselves as statements about the company’s outlook.

Risks investors should monitor

• Dependence on XDEMVY: All Q2 revenue came from XDEMVY net product sales, leaving current financial performance heavily dependent on continued prescription growth and commercialization of this product.
• Expense growth: R&D and SG&A expenses rose rapidly as Tarsus expanded advertising, patient support, staffing and clinical programs. Continued growth in these costs could delay sustained profitability even if revenue increases.
• Clinical-development risk: TP-04, TP-05, IRX-101 and ALK-001 remain investigational. Delays, unfavorable results or regulatory setbacks could reduce the expected benefits of the company’s pipeline investment.
• Acquisition and capital requirements: Tarsus is expanding through the completed iRenix acquisition and pending Alkeus transaction while continuing to report net losses. The financial and operational demands of these programs could increase future capital requirements.
• Gross-margin pressure: Gross margin slipped to 93% from 94% as manufacturing, royalty and milestone-amortization costs increased. Further changes in these costs or gross-to-net discounts could affect how much revenue growth converts into gross profit.

Summary

Tarsus delivered another quarter of rapid XDEMVY growth and raised its full-year sales guidance, supported by higher volume, better gross-to-net discounts and deeper prescriber adoption. The main constraint was spending: commercial expansion and pipeline development absorbed most of the additional gross profit, leaving the company with a smaller but continuing net loss. Future results will depend on sustaining XDEMVY adoption while managing expenses and advancing the enlarged clinical pipeline.